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Pneumonia kills more children each year worldwide than any other disease. Nonetheless, accurately determining the causes of child-
hood pneumonia has remained elusive. Over the past century, the focus of pneumonia etiology research has shifted from studies of 
lung aspirates and postmortem specimens intent on identifying pneumococcal disease to studies of multiple specimen types distant 
from the lung that are tested for multiple pathogens. Some major challenges facing modern pneumonia etiology studies include 
the use of nonspecific and variable case definitions, poor access to pathologic lung tissue and to specimens from fatal cases, poor 
diagnostic accuracy of assays (especially when testing nonpulmonary specimens), and the interpretation of results when multiple 
pathogens are detected in a given individual. The future of childhood pneumonia etiology research will likely require integrating data 
from complementary approaches, including applications of advanced molecular diagnostics and vaccine probe studies, as well as a 
renewed emphasis on lung aspirates from radiologically confirmed pneumonia and postmortem examinations.
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Over the past century, findings of pneumonia etiology studies 
in children have swung from detection of only bacteria to a 
preponderance of viruses. This apparent change in the micro-
bial etiology of pneumonia is attributable, perhaps, as much to 
changes in study design and methodology as to true changes 
in etiology. The same can be said when comparing the results 
across recent pneumonia etiology studies. Interpretation and 
comparison of results from studies that use different case defi-
nitions, study designs, specimen collection approaches, and 
diagnostic tests require recognition of the biases inherent in 
each approach. Yet, the challenges of determining pneumonia 
etiology extend beyond controlling for bias. The syndrome of 
pneumonia is inherently challenging to define and diagnose, 
and its pathogenesis is complex.
In this article, we explore the challenges of determining the 
microbial etiology of pneumonia, starting with a brief history 
of pneumonia etiology studies, with particular emphasis on the 
challenges faced by each era of research. We then enumerate the 
principal enduring challenges, demonstrating how each chal-
lenge can influence results. Finally, we comment on approaches 
for future research that could resolve the challenges.
HISTORY OF PNEUMONIA ETIOLOGY STUDIES
Early Focus on the Pneumococcus
Streptococcus pneumoniae, the most important cause of lobar 
pneumonia, was first identified in 1881 from samples of human 
saliva. Although it caused “sputum septicaemia” when inocu-
lated into rabbits, S. pneumoniae was not recognized as a human 
pathogen for several years [1, 2]. The first claims for a “mic-
rococcus of pneumonia” were made by Carl Freidländer, who 
observed diplococci in lung sections from 8 fatal cases in 1882 
[3]. In 1883, he cultured “cocci” from animal lung tissue, which 
were in fact Klebsiella pneumoniae—an organism that grew 
more avidly on the media used and, being short bacilli found 
in pairs, were confused with the pneumococcus when scientists 
used methods of the time [4]. In the same year, lung aspirates 
were first performed in living pneumonia patients, and oval 
diplococci were observed in the lung exudate [5, 6]. Isolation of 
these lung diplococci and demonstration of their animal patho-
genicity by Albert Fränkel in 1886 led to the proper assignation 
of etiology and also to the name—pneumococcus [7].
Early pneumonia etiology studies focused on adults, and 
at that time, pneumococcus was the dominant pathogen. 
Pneumococcal serotypes were numbered in the order in which 
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they were discovered, and these early serotypes tended to 
cause epidemics of pneumonia in adults (eg, serotypes 1, 2, 5). 
Because these “adult epidemic types” rarely colonize the naso-
pharynx of healthy individuals (unlike most other serotypes), 
the specificity of sputum culture for pneumonia etiology was 
high in the early studies among adults. This combination of 
high pneumococcal prevalence and high etiologic specificity 
gave sputum culture a useful positive predictive value for pneu-
mococcal pneumonia. In a 1926 series of 2000 adult pneumonia 
cases from Bellevue Hospital in New York City, pneumococci 
were found in 95% (mostly sputa) [8]. In a study of 1561 cases 
at Boston City Hospital in 1933, 98% were attributed to the 
pneumococcus; 307 of these patients underwent autopsy, and 
S. pneumoniae was cultured from 220 cadavers in either blood 
or lung material [9]. The prevalence of pneumococcus among 
cultures from sputum, lung aspirate, and blood from infants 
and children with pneumonia was slightly lower than in adults 
but still high; in New York City from 1928 to 1936, pneumo-
cocci were found in 923 (53.9%) of 1712 episodes [10].
The development and evaluation of horse serum therapy for 
pneumococcal pneumonia during the 1920s lent urgency to 
determining etiology and, if pneumococcal, to identifying the 
serotype. In general, isolates were obtained from sputum cul-
tures, but it was recognized that lung material, aspirated by per-
cutaneous needles, provided more accurate information and, 
importantly, may be the only specimen available in young chil-
dren who swallow rather than expectorate their sputum. In New 
York, between 1928 and 1936, Bullowa pioneered both lung 
aspiration and serum therapy, reporting 405 such procedures in 
children and nearly 1500 in adults [10].
The Advent of Antibiotics
When sulphonamides and penicillin replaced serum therapy as 
standard treatment for pneumonia in the 1940s, the incentive 
to define the infecting organism in individual cases receded, 
as did the effort to develop pneumococcal vaccines. There are 
few published studies of pneumonia etiology in the subsequent 
30 years. In 1967 the first case of pneumonia caused by a pneu-
mococcus resistant to penicillin was reported in Australia [11], 
but the clinical and epidemiological significance of this report 
was not appreciated for many years. In fact, the stimulus to 
re-examine etiology across the world was the desire to make 
appropriate life-saving antibiotics more widely available to chil-
dren to reduce the mortality rate in low-income settings. In the 
1980s, the first etiology studies in developing countries were 
conducted using blood and lung aspirate cultures that focused 
on bacterial etiologies. In The Gambia, bacteria were cultured 
in 33 (65%) of 51 children investigated [12]. In Papua New 
Guinea, 51 (61%) of 83 children had positive cultures; 32 had 
Haemophilus influenzae, and 28 had S. pneumoniae, including 
10 who had both [13]. The salient feature of these studies was 
their focus on radiologically evident pneumonia in children 
with no prior exposure to antibiotics. Indeed, some studies 
at the time showed that antibiotic treatment of pneumonia in 
developing countries, using a nonspecific clinical case defini-
tion, could reduce mortality, affirming the important role of 
bacteria in causing severe pneumonia [14].
The World Health Organization (WHO) used these data 
to develop a policy for case management of acute respiratory 
illness. They created a clinical case definition for pneumonia 
not based on radiographic findings, in contrast to the pneumo-
nia etiology studies on which the policy was derived [12, 13]. 
The WHO clinical case definition for pneumonia deliberately 
increased sensitivity to ensure that no child with pneumonia 
should miss the opportunity for effective antibiotic therapy, 
and this decreased the specificity for lung infection [15]. In 
the WHO case definitions, “severe pneumonia” was defined 
by a single clinical characteristic, lower-chest-wall indrawing; 
“non-severe pneumonia” was defined by tachypnea. Inevitably, 
by using these definitions for case management, the propor-
tion of children with pneumonia would have been lower and 
the proportion with a bacterial cause of pneumonia would have 
been substantially lower than in the studies used to originate 
the policy.
Early access to antibiotics presented a difficulty for research 
on pneumonia etiology. Evidence of prior treatment with anti-
biotics is associated with a 30% reduction in blood culture 
positivity in children with pneumonia [16], and this may have 
downgraded the prevailing perception of bacteria as the pri-
mary cause of pneumonia. In addition, etiology research in the 
1980s and 1990s adopted the WHO clinical management case 
definitions, which led to the inclusion of many children who 
did not actually have pneumonia. Furthermore, studies in this 
era started to expand the diagnostic testing repertoire to include 
tests of nasopharyngeal secretions and serological assays. The 
interpretation of these testing methods was often challenging. 
Regardless, viruses and bacteria were found in a large propor-
tion of cases using these techniques, with most studies focused 
on a single pathogen of interest [13, 17–20].
Identification of Multiple Pathogens
In 1983, the Board of Science and Technology for International 
Development (BOSTID) at the National Academy of Sciences, 
United States, commissioned a study of acute respiratory infec-
tion (ARI) (rather than “pneumonia”) etiology in 10 centers 
from developing countries [21]. Viruses were cultured from 
nasopharyngeal aspirates, and bacteria were detected in blood 
and pleural fluid by culture and in urine by counter-immunoe-
lectrophoresis [22]. Although the BOSTID study had a core 
protocol, this was adapted at the different study sites, resulting 
in a variety of definitions of ARI, some of which included cases 
with upper respiratory infections. Not surprisingly, case-fatality 
ratios were low due to the inclusion of less severe cases. Lung 
aspirates were not performed. Viruses were recovered more 
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frequently than bacteria, and detection of multiple potential 
pathogens in individual patients was common. Respiratory syn-
cytial virus was the most common virus detected, and S. pneu-
moniae and H.  influenzae were the most commonly detected 
bacteria. Although the BOSTID studies struggled with how to 
interpret and present their findings of multiple pathogens, the 
studies raised the possibility of the synergistic roles of viruses 
and bacteria in the pathogenesis of ARI.
To capture evidence on a greater number of potential path-
ogens, pneumonia studies since the BOSTID era have tested 
a wider range of clinical specimens with an increasing array 
of methods. For example, a 2002 study of human immuno-
deficiency virus (HIV)–infected and uninfected children in 
Durban obtained blood cultures, nasopharyngeal aspirates, 
induced sputum, gastric washings (for Mycobacterium tubercu-
losis), pleural fluid, and nonbronchoscopic bronchoalveolar lav-
age fluid [16]. Of 308 children with a complete set of specimens, 
141 (46%), 53 (17%), and 4 (1%) had 1, 2, and 4 pathogens iden-
tified, respectively [16].
Over the last 15 years there have been tremendous advances 
in the detection of microorganisms through nucleic acid detec-
tion techniques [23]. It is now possible to run high-throughput 
polymerase chain reaction (PCR) panels that can simultane-
ously detect very low levels of multiple bacterial and viral tar-
gets. Not surprisingly, studies using these multiplex PCR panels 
to test nasopharyngeal specimens have frequently detected 
multiple potential pathogens within individual cases [24–27]. 
Combining many tests, most with imperfect clinical specific-
ity, leads to an accumulation of false-positive results, creating a 
background noise from which it is difficult to discern the true 
signals of pneumonia etiology. As is discussed in a compan-
ion article [28], it is not until very recently that studies have 
also sampled nonpneumonia controls contemporaneously with 
pneumonia cases; case–control studies permit an assessment of 
the strength of association between a positive test and clinical 
pneumonia, but the resultant odds ratio is not readily interpret-
able for causality [24, 25, 27, 29].
Vaccine Probe Studies
If a pathogen-specific intervention can prevent pneumonia, 
it provides strong evidence for that pathogen’s role in causing 
pneumonia, although it may not be an exclusive role. This is 
the rationale behind vaccine probe studies [30]. For example, 
in a randomized controlled trial of the conjugate H. influenzae 
type B (Hib) vaccine in The Gambia, the risk of radiologically 
confirmed pneumonia was 21% lower among vaccine recip-
ients than controls [31]. This provides evidence that at least 
21% of cases of pneumonia, whose etiology is unknown, were 
“caused by” Hib. The true fraction is likely to be even greater 
because the efficacy of the vaccine against Hib pneumonia is 
almost certainly <100% [30]. Such studies have confirmed and 
quantified the dominance of Hib and pneumococcus as causes 
of radiologically confirmed pneumonia in children from sev-
eral continents. However, the proportion of cases of clinically 
defined pneumonia prevented by Hib or pneumococcal vac-
cines is much smaller because this definition is less specific for 
true lung infection [30, 32–36]. The vaccine probe technique 
also has the potential to explore causal pathways and pathogen 
interactions in pneumonia. For example, it can be used to test 
whether vaccines against influenza are able to reduce the sub-
sequent incidence of pneumococcal pneumonia. Furthermore, 
the probe need not be a vaccine, as demonstrated recently by 
the use of prophylactic monoclonal antibody infusions for the 
prevention of hospitalizations and outpatient visits caused by 
respiratory syncytial virus [33].
The history of pneumonia etiology studies over the last cen-
tury shows several trends: from the use of highly specific tests 
on specimens from the lung itself to highly sensitive tests on 
samples of body fluids distant from the lung; from detection of 
single pathogens to detection of multiple pathogens; and from 
an exclusive focus on bacteria to enhanced detection of viruses 
(Figure 1). Although some challenges facing early investigators 
(eg, poor viral diagnostics) have improved, others have endured 
(eg, variable case definitions) or worsened (eg, lack of lung tis-
sue). We now discuss the major challenges hampering pneu-
monia etiology research today, appreciating the history of these 
current challenges.
CHALLENGES IN CURRENT PNEUMONIA ETIOLOGY 
STUDIES
Case Definitions Defining Different Syndromes
Unlike case definitions for acute gastroenteritis and febrile 
illness that are based on the presence of a specific symptom 
(eg, diarrhea) or sign (eg, fever), case definitions for pneu-
monia define a syndrome that is irreducible to a single, or 
even a constellation of, signs and/or symptoms. As already 
mentioned, WHO created a standardized clinical case man-
agement definition for children with suspected pneumonia 
in the 1980s, placing a priority on sensitivity rather than the 
specificity achieved in earlier radiologically based defini-
tions [15]. Throughout this article, we refer to sensitivity of a 
case definition (or test) as the percentage of all children with 
pneumonia who are identified. On the other hand, specific-
ity refers to the percentage of all children without pneumonia 
who do not meet a case definition (or did not have a positive 
test result). High sensitivity usually comes at the expense of 
misdiagnosing some children without pneumonia as having 
pneumonia (false positives); high specificity usually comes at 
the expense of missing some children who have pneumonia 
(false negatives). Although the WHO’s sensitive case defini-
tion was developed to maximize the likelihood that children 
with pneumonia would be treated with antibiotics in periph-
eral health facilities that lack radiologic capacity, it has been 
co-opted for use in many pneumonia etiology and disease 
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burden studies. Using the WHO case management defini-
tions results in misclassification, an acceptable consequence 
in the clinical setting, but a problematic one in the research 
setting. Many children with conditions other than pneumo-
nia (eg, sepsis, malaria, upper respiratory tract infections) 
will be included as pneumonia cases; the pathogens detected 
in these children will therefore be falsely ascribed as caus-
ing pneumonia. Another problem is the variety of pneumo-
nia case definitions used in etiology studies. In a review of 
pneumonia etiology studies done since the year 2000, 61% of 
the 153 studies used WHO clinical case definitions. However, 
even among these studies, not all chose the same definition, 
with some including definitions for “very severe pneumonia,” 
some “severe pneumonia,” and some “nonsevere pneumonia” 
[37]. Half also required the presence of a chest radiographic 
abnormality, whereas others required evidence of acute infec-
tion (eg, fever, leukocytosis) [38]. Just under half of the stud-
ies included children with wheezing, which is likely to include 
more cases with viral infections. Some studies side-stepped all 
of these rule-based definitions by using a definition of “phy-
sician-diagnosed pneumonia” [39]. Such heterogeneity in case 
definitions leads to incomparability of etiology results.
Not All Cases Sampled, Especially Fatal Cases
A study may not accurately represent the full distribution of 
pneumonia etiologies if certain types of patients or certain 
types of specimens are investigated less frequently. For example, 
if there is a likelihood of collecting body fluid samples more 
commonly from more severe cases, this biases etiologic distri-
butions toward those more likely to cause severe pneumonia. 
A more entrenched limitation, however, is that specimens from 
fatal pneumonia cases are underrepresented in etiology studies. 
Fatal cases likely have a different etiologic pattern than nonfatal 
cases, and studies solely focused on the latter will not accurately 
represent the causes of fatal pneumonia.
There are several reasons for the underrepresentation of 
fatal cases in pneumonia etiology studies. First, in many set-
tings where healthcare utilization is poor, the sickest children 
die before presentation to the hospital, and few studies have 
investigated etiology among cases identified outside of health 
facilities. At the time of presentation to the hospital, the most 
critically ill cases are often not enrolled in etiology studies due 
to the urgent need for resuscitation and the reluctance to per-
form research procedures perceived as potentially adversely 
affecting the child’s precarious clinical condition. Moreover, the 
sickest children often die soon after presentation before they can 
be enrolled or before specimens can be collected. Postmortem 
specimens are rarely collected. In a pneumonia etiology study in 
Kilifi, Kenya, children who met eligibility criteria but who were 
not enrolled had a case-fatality ratio of 18% compared with 4% 
among those enrolled, illustrating the survivorship bias [26]. 
Researchers are left to extrapolate the causes of fatal pneumonia 
from the most severe cases enrolled, which leads to uncertainty 
about the true causes of pneumonia mortality.
Not All Specimen Types Collected
The reported etiologies of pneumonia are strongly influenced 
by the types of clinical specimens collected. Sterile-site speci-
mens have been the gold standard for detection of bacterial 
pneumonia, although their poor sensitivity is well established. 
Upper respiratory tract samples will detect both viruses and 
bacteria, although their etiologic significance is questionable. 
Some pathogens are preferentially identified in oropharyn-
geal swabs, compared with nasopharyngeal swabs, such as 
Mycoplasma pneumoniae [40]. Tuberculosis is most often diag-
nosed in children by testing induced sputum or gastric aspi-
rates. Pneumocystis pneumonia is most definitively identified 
by bronchoalveolar lavage or induced sputum. A review of pub-
lished pneumonia etiology studies from 2000–2010 revealed 
that 77% collected blood and 15% collected pleural fluid [37]. 
Figure 1. Changes in challenges to pneumonia etiology studies over time, 1930–2016.
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Upper respiratory tract specimens were collected in approxi-
mately half of studies; only 10% collected induced sputum.
Likelihood of Seeking Care for Pneumonia Differs by Site
Healthcare utilization practices vary widely around the world 
[41]. In some cultures, parents seek care early, particularly for 
young children, whereas in other settings, parents seek reme-
dies for their child’s mild illness at a traditional healer and only 
present to hospital if this approach fails. In some low-income 
countries, access is also limited by distance, cost, or time consid-
erations [42]. In such settings, children often present late in the 
course of illness, when their clinical status has become severe or 
even moribund [43]. In studies of children who present early in 
the course of illness, the contribution of pathogens that cause 
mild or moderate pneumonia, such as some viruses, will domi-
nate. In contrast, in studies of children who arrive at hospital late 
in the course of illness, the etiologic spectrum will reflect patho-
gens causing severe pneumonia, particularly bacteria. Although 
pneumonia etiology studies at both extremes might accurately 
represent the causes of hospitalized pneumonia in each setting, 
they are not necessarily describing the same clinical syndrome 
or the full etiologic spectrum of pneumonia in the community.
Cross-Sectional Designs Cannot Describe the Causal Chain of Pneumonia
The majority of pneumonia etiology studies are cross-sectional 
in design, whereby specimens are collected at the time of admis-
sion or presentation to a health facility. Sampling at 1 point in 
time will fail to detect the causative pathogen if that pathogen 
has already been cleared from the sample (eg, bacteria in the 
blood). Moreover, cross-sectional designs provide little infor-
mation on the causal chain of pneumonia or the synergistic role 
of multiple pathogens in causation. There is considerable evi-
dence that influenza virus can damage the respiratory epithe-
lial cells, making a person susceptible to a subsequent bacterial 
pneumonia [44–47]. Other viruses, such as parainfluenza virus 
and adenovirus, have also been implicated as playing a causal 
role in subsequent bacterial pneumonia [48, 49].
Specimens Distant From the Site of Infection
Lung aspirates are now rarely performed in either clinical prac-
tice or pneumonia etiology studies. Pneumonia diagnosis now 
relies on findings from specimens indirectly from or peripheral 
to the site of infection, such as blood, induced sputum, naso-
pharyngeal and oropharyngeal secretions, gastric aspirates, or 
urine [50–52].
Samples not obtained directly from the lung pose problems 
of both sensitivity and specificity in assigning pneumonia eti-
ology. A positive bacterial culture in the blood of a patient with 
clinical pneumonia is widely accepted to indicate pneumonia 
etiology. However, the blood culture is only positive in a small 
fraction (approximately 10%) of true bacterial pneumonia 
cases, making blood culture an insensitive diagnostic test [32]. 
Secretions from the lower respiratory tract of children with 
pneumonia offer diagnostic promise because of their origin 
in the lung and their ability to be collected in a noninvasive 
manner (ie, induced sputum). However, the inferential value 
of this specimen is critically dependent on the collection of a 
true lower respiratory tract specimen free of contamination 
by upper respiratory tract secretions, an outcome difficult to 
achieve [53].
Upper respiratory tract specimens pose a particular problem 
in pneumonia diagnostics. Because these specimens are easy 
to obtain, they are now commonly used to assess and infer the 
cause of pneumonia [37]. Polymerase chain reaction of upper 
respiratory tract specimens has high sensitivity but low specific-
ity for establishing pneumonia etiology for most pathogens [23, 
29]. Because most viruses that can cause pneumonia more often 
cause upper respiratory tract infections, detection of a virus in 
the upper respiratory tract of a pneumonia patient might only 
represent infection of the upper respiratory tract. Moreover, 
detection of viral nucleic acid might indicate asymptomatic 
infection or prolonged shedding from a resolved illness episode 
rather than current symptomatic infection. Detecting some 
common bacteria (eg, pneumococcus, Moraxella catarrhalis) 
in the upper respiratory tract often depicts a state of commen-
sal colonization rather than illness. In many developing coun-
try settings, pneumococci can be found in the nasopharynx 
of almost all children, regardless of the presence of symptoms 
[54]. Strategies such as quantification of pathogen load, strain 
identification, and assessment of attributable fraction have been 
used to overcome the specificity problem of upper respiratory 
specimens and are described elsewhere [28, 29, 55, 56].
Antibiotic Pretreatment
Microbiologic diagnosis of the cause of pneumonia is also ham-
pered by the frequent use of outpatient antibiotics, which are 
available without a prescription in some locations. Antibiotic 
pretreatment further decreases the sensitivity of bacterial 
cultures [16]. The magnitude of this effect is not well quanti-
fied and likely varies depending on the type of antibiotic, the 
duration of antibiotic use prior to specimen collection, and 
the susceptibility of the pathogen. Regardless, antibiotic use 
prior to specimen collection leads to an underestimation of the 
proportion of pneumonia cases attributed to bacterial causes. 
Designing etiology studies in a way that accounts for or adjusts 
for this effect is challenging because accurate information on 
antibiotic pretreatment is difficult to obtain. Parental history 
is unreliable, bioassays of serum are insensitive because of the 
high rate of clearance from the serum, and timely urine speci-
mens are difficult to obtain from ill, often dehydrated, children.
Variability in Method and Number of Pathogens Tested
The findings on etiologic distribution of pneumonia are 
dependent on which pathogens are included in the testing 
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panel. Obviously, etiology cannot be attributed to a pathogen 
not tested for. Testing for only 1 or 2 pathogens will overestimate 
the causal role of these pathogens because studies usually assign 
complete causal attribution when detected. On the other hand, 
addition of multiple tests with less than perfect specificity for 
many pathogens, particularly of low prevalence as true causes 
of pneumonia, will lead to a greater likelihood of false-posi-
tive results and the sharing of causal attribution between true 
pneumonia-causing pathogens and those of less clear etiologic 
significance. Although bacterial culture does not require inves-
tigators to limit the number of bacteria tested for, using PCR in 
etiology studies dictates an a priori list of putative pathogens, 
which might include some pathogens that actually do not cause 
pneumonia while excluding others that do. Nontargeted detec-
tion methods (eg, metagenomics) avoid the latter problem but 
raise further dilemmas of interpretability of multiple pathogen 
detection in nonsterile sites [57, 58].
The picture of etiology is also determined by the perfor-
mance characteristics of the assays used. For bacterial culture, 
the choice of and quality of media substantially influences the 
pathogens that are detectable and can lead to incorrect conclu-
sions on pathogen prevalence (eg, appropriate blood agar for 
pneumococcus). Polymerase chain reaction assay performance 
can vary for the same pathogen [59]. Measurement error is dif-
ficult to estimate and is therefore rarely incorporated into the 
analysis of etiology.
Multiple Pathogens
Although Occam’s razor favors the hypothesis with the fewest 
assumptions (eg, that a pneumonia episode is caused by a single 
pathogen), in the case of pneumonia, biology seems reluctant to 
comply with this premise. There is abundant evidence that viral 
infections can predispose an individual to bacterial pneumonia 
[47, 48]. Yet, assigning multiple pathogens as the cause of pneu-
monia remains a methodologic and analytic challenge. Some 
pathogens might play a role early in the course of pneumonia 
and be gone from the sampled body site by the time the pneu-
monic process manifests. On the other hand, highly sensitive 
assays of the upper respiratory tract can identify multiple path-
ogens of unclear etiologic significance in the same individual. 
Even finding >1 pathogen in what is usually considered a sterile 
site, like blood, does not assure that each is playing a causal role 
in the lung infection. Moreover, recent evidence from non-cul-
ture-based detection methods has challenged the long-standing 
notion that the lung itself is a sterile site; the healthy lung likely 
has its own microbiome and might also experience the transient 
presence of putative pneumonia pathogens, perhaps through 
microaspiration of upper respiratory tract flora, of unclear 
pathophysiologic significance [57, 58, 60, 61].
Faced with the challenge of attributing etiology, some 
researchers report all combinations of pathogens detected 
in pneumonia cases [21, 38]. Although true to the data, this 
option results in a long list of pathogen combinations that does 
not lend itself to a clear understanding of actual etiology or to 
optimal treatment and prevention strategies [38, 62]. Analytic 
approaches that attempt, in part, to assign population-level and 
individual-level causality to each pathogen have been devel-
oped and are described in more detail in another article in this 
supplement [28].
AVERTING THE CHALLENGES IN FUTURE ETIOLOGY 
STUDIES
There have been many technological and methodological 
advances since the days of culturing pneumococcus for the 
purpose of horse serum therapy. Although many more path-
ogens can now be detected and modern assays have substan-
tially higher sensitivity than older tests, the specimens most 
commonly sampled now are less directly related to the site of 
infection than the lung aspirates used in earlier decades. This 
evolution in specimens collected, methods for testing, and 
range of pathogens tested for poses a challenge of integrating a 
plethora of data of variable accuracy into an analysis from which 
meaningful biologic inferences can be drawn about etiology.
We suggest several approaches and needs for the future of 
pneumonia etiology studies.
1. Lung aspirates should be formally evaluated, and if found 
to be safe and beneficial, considered for wider use. Lung 
material remains the most useful specimen because it is a 
sample from the site of infection. Lung aspirate procedures 
have been shown to have a good safety profile in well-trained 
hands, yield results that can improve acute care for the indi-
vidual patient, and have high value for pneumonia etiology 
studies. Several research groups have recently returned to 
this gold-standard diagnostic and applied new molecular 
diagnostic assays to sampled lung tissue. These studies show 
the presence of multiple pathogens in the lungs of children 
with pneumonia [63, 64]. As mentioned, current thinking 
no longer holds the lung to be a sterile site, complicating 
interpretation of finding pathogens even in the lung. Clinical 
outcomes of those who have undergone lung aspirate should 
be documented and, if possible, compared with outcomes 
of similar patients who did not undergo the procedure to 
evaluate whether lung aspirates either harmed (eg, excess 
pneumothoraces) or benefited (eg, more targeted antibiotic 
therapy) a population of pneumonia patients. If found to be 
safe and beneficial, consideration should be given to expand 
the collection of lung aspirates and to possibly extend their 
collection to a broader distribution of pneumonia cases, 
beyond those with a large, peripheral, consolidated infiltrate 
on chest radiograph.
2. Pneumonia etiology studies should prioritize the examina-
tion of fatal cases. Postmortem evaluations, especially limited 
to examination of the chest, and collection of nasopharyngeal 
Downloaded from https://academic.oup.com/cid/article-abstract/64/suppl_3/S188/3858225
by London School of Hygiene & Tropical Medicine user
on 26 January 2018
S194 • CID 2017:64 (Suppl 3) • Feikin et al
and blood specimens in the immediate postmortem period 
are likely to be highly informative [65]. An autopsy study 
of 290 Zambian children with a clinical diagnosis of pneu-
monia in 2002 diagnosed pyogenic pneumonia in approxi-
mately half of all cases but also found a sizeable number of 
cases with other pathology, such as pulmonary edema and 
shock lung, indicative of clinical misclassification during life 
[66]. Surprisingly, a quarter of all HIV-uninfected children 
had tuberculosis. Although postmortem samples can add to 
our knowledge, they have their own set of limitations, such 
as high rates of refusal, lack of clarity regarding initial etiol-
ogy among cases with prolonged hospital courses, and con-
tamination by postmortem bacterial overgrowth. The use 
of autopsies, including minimally invasive studies, are now 
the centerpiece of a new initiative to determine the cause of 
death in a network of surveillance sites in Africa and Asia 
[67, 68]. Because postmortem pneumonia studies by defini-
tion exclude surviving severe pneumonia cases, their contri-
bution to describing severe pneumonia etiology should be 
complemented with data from the majority of studies that 
describe predominantly nonfatal pneumonia cases.
3. Pneumonia etiology studies should use case definitions 
based on radiologic evidence. In studies of pneumonia eti-
ology, the shift toward application of the WHO clinical case 
management definitions has led to misclassification of other 
respiratory and nonrespiratory illnesses as pneumonia. The 
proportion of misclassified cases can be substantial, and 
assignment of causality to these cases can result in inaccu-
rate etiologic determinations, leading to misguided clinical 
or public health interventions. Evidence of lung parenchy-
mal involvement on chest radiograph, although imperfect, 
is the most accurate and accessible indicator of pneumonia. 
Although clinical case definitions still have a role in clini-
cal management, efforts should be made to characterize the 
nature and etiology of the nonpneumonia illnesses captured 
by those definitions.
4. We need to develop a better understanding of the patho-
genesis of pneumonia. The causal chain of pneumonia 
and the role of multiple pathogens in that chain remain a 
refractory enigma. Basic questions remain unresolved. Can 
viruses cause severe pneumonia on their own? Can bacteria 
cause pneumonia without a preceding viral infection? What 
host-related factors enable a pathogen or multiple pathogens 
to cause pneumonia and in what sequence? Why does a dom-
inant species emerge from the lung ecosystem in pneumo-
nia? Is there a set of immunologic responses to microbiota 
that distinguishes asymptomatic infection from disease, and 
if so, are these responses specific enough for certain patho-
gens to be used diagnostically [69]? The vast majority of past 
pneumonia etiology studies used a cross-sectional design 
that is unable to answer these questions. Prospective studies 
with recurrent longitudinal sampling are resource-intensive, 
underpowered to detect a rare outcome like pneumonia, and 
still susceptible to unclear interpretation of pathogen detec-
tion. Therefore insights into pathogenesis might be most 
likely found in the controlled experimental conditions of 
animal studies. The vaccine probe approach, which yielded 
insights into the etiologic fraction of pneumonia caused by 
Hib and pneumococcus [30], can potentially be extended 
further in clarifying the causal direction of relationships 
between pathogens causing disease. Although probe studies 
provide strong evidence of causality, they are limited by the 
small number of highly effective pathogen-specific inter-
ventions available [30]. Ultimately, a better understanding 
of how pneumonia occurs can direct the types of tests we 
do and how they are interpreted with regard to pneumonia 
etiology.
Over the past century of pneumonia etiology studies, we 
have seen that as some challenges are resolved, others arise. 
For example, as the focus moved from pneumococcus only to 
multiple pathogens detected in sites distant from the lung, the 
attribution of etiology became more complex. Alternatively, 
some challenges exacerbate others. The use of a nonspecific 
clinical case definition in pneumonia etiology studies made the 
interpretation of nonspecific tests (eg, PCR of nasopharyngeal 
specimens) more troublesome. History also demonstrates that 
no single study is able to solve all of the challenges of pneumo-
nia etiology. More likely, the most comprehensive picture of 
pneumonia etiology will need to come from piecing together 
different, complementary studies, such as cross-sectional stud-
ies, postmortem studies, probe studies, lung aspirate studies, 
and animal models. Ultimately, efforts to overcome the chal-
lenges of pneumonia etiology studies of the past could have 
meaningful impact in pneumonia treatment and prevention in 
the future.
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